Related Experiment Video
Updated: Dec 28, 2025
08:49
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
9.4K
c-Jun N-Terminal Kinase Signaling Inhibitors Under Development
1Drug Discovery Division, Korea Research Institute of Chemical Technology, 19, Sinseongno, Yuseong-gu, Daejeon, 305-343 Korea.
Toxicological Research
|February 11, 2020
Summary
This review covers c-Jun N-terminal kinase (JNK) inhibitors for novel therapies. It discusses small molecule and peptide inhibitors like SP-600125, CC-401, CEP-1347, and D-JNKI-1, along with their therapeutic potential and safety.
Area of Science:
- Pharmacology
- Molecular Biology
- Drug Discovery
Background:
- Protein kinases, including c-Jun N-terminal kinases (JNKs), are key targets in drug discovery.
- JNK signaling pathways are implicated in various diseases, making them attractive therapeutic targets.
Purpose of the Study:
- To review the current status of JNK inhibitors.
- To discuss the therapeutic potential and safety issues associated with JNK inhibitors.
Main Methods:
- Literature review of JNK inhibitors.
- Analysis of small molecule and peptide inhibitors.
- Examination of clinical trial data and preclinical studies.
Main Results:
- Several JNK inhibitors, including SP-600125, CC-401, CEP-1347, and D-JNKI-1, have been developed.
- These inhibitors show potential in treating inflammation, leukemia, Parkinson's disease, and hearing loss.
- Safety profiles and ongoing research are critical considerations.
Conclusions:
- JNK inhibitors represent a promising class of therapeutics for diverse diseases.
- Further research is needed to optimize efficacy and ensure safety for clinical application.
More Related Videos
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
11.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.6K
01:22PI3K/mTOR/AKT Signaling Pathway
5.1K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.1K
01:07MAPK Signaling Cascades
7.7K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.7K
01:25cAMP-dependent Protein Kinase Pathways
8.1K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.1K
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
03:03mTOR Signaling and Cancer Progression
4.5K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.5K